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Abstract The B cell arm of adaptive immunity under-
goes significant modifications with age. Elderly people
are characterized by impaired B cell responses reflected
in a reduced ability to effectively respond against
viruses and bacteria. Alterations of immunity with ad-
vancing age (immunosenescence) have been widely
studied in centenarians who are considered a good
example of successful aging. In recent years, attention
has shifted to centenarian offspring (CO) as a model of
people genetically advantaged for healthy aging and
longevity. Here, we describe the preliminary character-
ization of a proposed new population of memory B
cells, defined as CD19+CD38−CD24−, which we find
at higher frequencies in the elderly but less so in CO
than healthy age-matched random controls. In addition,
we found a decreased expression of RP105 (CD180), a
toll-like receptor-associated molecule, on these cells.
CD180 downregulation may potentially be a marker of
immunosenescence. Moreover, we show that these
CD19+CD38−CD24− B cells produce TNF and hypoth-
esize that their observed expansion in the elderly might
contribute to the increased inflammatory status some-
times designated “inflamm-aging.”
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Introduction
B cells are key mediators of immunity. The humoral
immune response includes production of antibodies
against pathogens and cytokines interacting with other
components of the immune system. Early stages of B
cell development occur in the bone marrow from
hematopoietic stem cells. The early progenitors of B
lymphocytes develop into pro-, pre-, and immature B
cells (LeBien and Tedder 2008) that, after they are
controlled for autoreactivity (Carsetti et al. 1995;
Palanichamy et al. 2009), leave the bone marrow and
enter the blood as transitional B cells (Allman et al.
1993; Chung et al. 2003; Mauri and Ehrestein 2008).
In humans, peripheral blood naïve and memory B cells
have been described on the basis of the differential
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expression of IgD and CD27 (Anolik et al. 2004; Shi et
al. 2005; Wei et al. 2007; Frasca et al. 2008), as follows:
IgD+CD27− cells are naïve; IgD+CD27+ cells are
memory cells including the unswitched memory cells
also known as marginal zone-like B cells (Weller et al.
2004) and the IgM+memoryB cell population identified
as IgM+IgD+CD27+; IgD−CD27+ cells are classical
switched memory B cells also including the “IgM-only”
memory B cells identified as IgM+IgD−CD27+, and
finally, IgD−CD27−, double-negative memory B cells
(Fecteau et al. 2006; Colonna-Romano et al. 2009).
More recently, a different flow cytometric approach
has been used to distinguish naïve from memory B cells
(Allman et al. 2001, 2004; Carsetti et al. 2004;
Palanichamy et al. 2009; Blair et al. 2010). The use of
two developmentally regulated markers, CD24 and
CD38, in association with the B-lineage marker CD19,
allowed the identification of three different B cell pop-
ulations: CD19+CD38highCD24high, the previously
mentioned transitional B cells that also include imma-
ture B cells; CD19+CD38intCD24int defined as mature B
cells; and the final step of maturation in the periphery,
CD19+CD38−CD24high so-called “primarily memory B
cells.” In a recent paper (Chaplin et al. 2011), differen-
tiation from transitional to mature B cells was induced
by stimulation with CD180 (RP105), a toll-like receptor
(TLR)-4 homologue expressed by monocytes, macro-
phages, dendritic cells, and B lymphocytes which regu-
lates TLR-4 signaling and induces B cell proliferation.
Many papers have focused on modifications of the
immune system in the elderly (immunosenescence) like-
ly to contribute to their increased morbidity and mortal-
ity. It has been widely reported that elderly people show
changes in B cell number, low levels of antibody pro-
duction, and poor responses to recall antigens, and a
collapse in B cell receptor repertoire diversity correlated
with poor health status and the impairment of antibody
response (Miller and Cancro 2007; Kumar and Burns
2008; Cancro et al. 2009; Gibson et al. 2009; Dunn-
Walters and Ademokun 2010; Frasca et al. 2010; Frasca
and Blomberg 2011; McElhaney et al. 2012). Lower
numbers and percentages of B cells also form part of
the cluster of immune parameters collectively known as
the “Immune Risk Profile” associated with 2-, 4-, and 6-
year mortality of the very elderly in the Swedish OCTO/
NONA longitudinal studies (Pawelec et al. 2005). We
and others have previously demonstrated that in elderly
people, IgD+CD27− naïve B cells are significantly re-
duced (Gupta et al. 2005; Colonna-Romano et al. 2008).
In contrast, Chong et al. (2005) demonstrated that the
percentage of circulating naïve B cells, identified as
CD27−, were significantly higher in the aged subjects
than young subjects. This topic is still a somewhat
controversial finding, as previously reviewed by us
(Bulati et al. 2011). Moreover, double-negative (DN)
B cells (IgD−CD27−) are significantly increased in the
elderly (Colonna-Romano et al. 2009; Bulati et al.
2011), as well as under certain pathological conditions,
such as systemic lupus erythematosus (SLE) (Anolik et
al. 2004;Wei et al. 2007), chronic HIV infection (Cagigi
et al. 2009), and in healthy subjects challenged with
respiratory syncytial virus (Sanz et al. 2008).
We have recently focused on some characteristics of
the naïve/memory B cell compartment of centenarian
offspring (CO). This is a special population of elderly
people that, like their centenarian parent(s), could have
genetic and functional advantages that predispose them
to healthy aging and longer survival (Terry et al. 2003,
2004). We have shown that CO fail to show the age-
associated increase of DN (IgD−CD27−) B cells seen in
the general elderly population. Consistent with this, the
level of serum IgM in CO is within the range of the
levels observed in young subjects (Colonna-Romano et
al. 2010).
As outlined above, several distinct memory B cell
populations have been identified in humans, but asso-
ciations between their specific phenotype and their
functions remain to be clarified. Here, we report the
characterization of a proposed new population of
memory B cells identified as CD19+CD38−CD24−.
Moreover, we show that these cells are expanded in
the general elderly but not in CO who show similar
levels to those observed in young donors, suggesting a
more “youthful” B cell constellation. A more detailed
examination of CO B cells was then performed to
evaluate the expression of CD27, IgM, and IgD. It is
known that IgM memory B cells are reduced in the
elderly, thus predisposing them to pneumococcal in-
fection (Shi et al. 2005; Buffa et al. 2011). Here again,
we show that CO have a “younger” B cell profile.
Indeed, the percentage of these cells are not as reduced
in CO as in their age-matched controls and is more
similar to the percentage observed in young people.
Moreover, we have examined the expression of
CD180 on total B cells and found that elderly people
have a significant increase of the CD19+CD180− B
cell subset. Finally, we have evaluated the expression
of CD180 on B cell populations, identified by the
AGE
differential expression of IgD/CD27 and CD38/CD24,
in order to determine the age-related modulation of
this marker on these cells.
Material and methods
Subjects
A total of 35 healthy Sicilians were included in the
study. Twelve subjects aged 70.1±8.3 years, who were
the offspring of at least one centenarian parent, were
compared with seven age-matched controls without a
centenarian parent (aged 69.1±9 years), eight young
(28.5±1.9 years), and eight old (86.4±3.8 years). All
subjects were in good health according to their clinical
history, and none of them had neoplastic, infectious, or
autoimmune diseases or received any medications influ-
encing immune function at the time of the study. The
study received approval from the local ethics committee,
and all participants gave their informed consent.
Whole blood was collected by venepuncture in
vacutainer tubes containing ethylenediaminetetraace-
tic acid (EDTA). Peripheral blood mononuclear cells
(PBMC) were isolated by density gradient centrifuga-
tion on Ficoll-Lympholyte (Cedarlane Laboratories
Limited, Ontario, Canada) and stored frozen.
Flow cytometric immunophenotyping of B cell subsets
from human peripheral blood of young, elderly,
centenarian offspring, and age-matched controls
To characterize the phenotype of B lymphocyte subsets,
extracellular labeling was performed with anti-CD19-
PE, CD24-Pe-Cy7, CD5-V450, IgD-FITC, IgM-PerCP-
Cy5.5 (BD Biosciences), CD27-Qdot605 (Invitrogen),
and CD38-eFluor650 (eBioscience). Cell viability was
determined with RedVid (Invitrogen). All staining steps
were performed in PBS, 2 % FCS, 2 mM EDTA, and
0.01%Na azide (PFEA) buffer. Blocking of nonspecific
binding sites was accomplished using human immuno-
globulin Gamunex (Bayer, Leverkusen, Germany) or
mouse serum (Caltag/Invitrogen, Karlsruhe, Germany).
For each experiment, cells or mouse/rat κ-chain Comp
Beads (Becton Dickinson) were stained with the
corresponding fluorochrome-labeled antibodies and in-
cubated for 20min at 4 °C in the dark. Human-unstained
cells were used as negative controls. After washing with
PFEA, the cells or beads were resuspended and
measured on a LSR-II flow cytometer using the acquisi-
tion software FACSDiva (Becton Dickinson). Data were
analyzed using FlowJo software (Tree Star, Portland,
OR). For data analysis, dead cells (RedVid-positive)
were excluded. CD19+ living cells were gated within
the side/forward scatter (SSC/FSC) lymphocyte gate.
Stimulation of PBMC with cytosine guanine/phorbol
myristate acetate/ionomycin for B cell IL-10, IL-6,
and TNF production
PBMC (106 cells/ml) were suspended in X-vivo 15
(Lonza,Walkersville,MD, USA)with or without cytosine
guanine (CpG)-B 2006 (3 μg/ml, Tib Molbiol), phorbol
myristate acetate (PMA) (50 ng/ml), ionomycin (1 mg/
ml), and monensin sodium salt (2 mM, Sigma Aldrich) in
24-well flat-bottom plates for 5 h, at 37 °C (CO2 5 %).
Cells were harvested, washed, and directly stained with
anti-CD19-PerCP-Cy5.5, CD24-Pe-Cy7, IgD-FITC,
CD180-PE (BD Biosciences), CD27-Qdot605
(Invitrogen), and CD38-eFluor650 (eBioscience). For in-
direct immunofluorescence, antihuman CD5 (clone
UCHT2) culture supernatant hybridoma cell line
(Zentrum für Medizinische Forschung, Tübingen,
Germany) was used as primary antibody. The secondary
antibody was rat anti-mouse PO (Invitrogen). Cells were
permeabilized with Citofix/Citoperm (BD Biosciences).
Finally, cells were stained with anti-IL-10-APC (Miltenyi
Biotec), TNF-AlexaFluor700, and IL-6-V450 (BD
Biosciences), washed, and analyzed.
Statistical analyses
All statistical analyses were performed with Graph Pad
Prism 4.0 using the Mann–Whitney nonparametric U
test to compare two independent groups. Statistical sig-
nificance was expressed as P<0.05, P<0.01, and P<
0.001 as shown in the figures. All values are expressed
as mean±standard error of the mean (SEM).
Results
Characterization of CD38±/CD24± B cell subsets
To better characterize the memory/naïve phenotype of
CD38±/CD24± B cell subsets, we have gated
CD19+CD38hiCD24hi “classical transitional,”
CD19+CD38in tCD24in t “mature naïve,” and
AGE
CD19+CD38−CD24+ “primarily memory” B cells and
further evaluated them on the basis of the expression
of IgD and CD27, widely used to identify naïve and
memory B cells (Fig. 1). Moreover, as a fourth popu-
lation that lacks both CD24 and CD38 is clearly pres-
ent, we also extended the IgD/CD27 characterization
to this population. In the figure, CD19+CD38++CD24−
plasma cel l s are a lso shown. Most of the
CD19+CD38hiCD24hi cells (plot I) are IgD+CD27−
(85.4 %), thus showing that classical transitional B
cells have a naïve phenotype, although about 12 %
of them are IgD−. Again, CD19+CD38intCD24int cells
(plot II) are principally IgD+CD27−, although about
15 % of them express CD27. Moreover, the
CD19+CD38−CD24+ B lymphocytes (plot III), here
referred to as primarily memory B cells, show a variety
of different phenotypes. Indeed, some of them (26.6 %)
are IgD+CD27+ (unswitched memory); others (44 %)
are IgD−CD27+ (switched memory); 25 % of them are
naïve as they express IgD but are negative for CD27
expression, and those that have a very low percentage
(4.3 %) are IgD−CD27− (DN). Our analysis of the fourth
population (CD19+CD38−CD24−) (plot IV) indicated
that these cells were predominantly IgD−, including
the IgD−CD27+ (switched memory) and the
IgD−CD27− (double negative) B cell subsets, although
8.3 % of them are naïve (IgD+CD27−). Therefore, dur-
ing maturation, it seems that B cells progressively mod-
ulate both CD38/CD24 and IgD/CD27 expressions,
although not synchronously. In order to characterize
these populations in more detail, we have evaluated the
expression of additional immunological markers (Fig. 2);
Fig. 1 Phenotypic characterization of CD38/CD24 B cell sub-
sets. CD19+CD38hiCD24hi (I), CD19+CD38intCD24int (II),
CD19+CD38−CD24+ (III), and CD19+CD38−CD24− (IV) were
evaluated on the basis of the expression of IgD and CD27.
Moreover, it is also depicted the gate of CD19+CD38++CD24−
plasma cells. In figure, the phenotypic characterization of an 82-
year-old sample is shown. For data analysis, dead cells (RedVid
positive) were excluded. CD19+ living cells were gated within
the SSC/FSC lymphocyte gate. The evaluation of CD38 and
CD24 within CD19+ B cells leads to the identification of four
naïve/memory B cell subsets. This kind of characterization
confirmed that the majority of CD19+CD38hiCD24hi have a
naïve (IgD+CD27−) phenotype, although about 12 % of them
are IgD−. The CD19+CD38intCD24int B cells are principally
naïve, whereas about 15 % of them express CD27. The analysis
of CD19+CD38−CD24+ B cells reveals a variety of different
phenotypes; some of them are IgD+CD27+ (unswitched memo-
ry); others are IgD−CD27+ (memory switched); about 25 % of
them are naïve as they express IgD, but lack CD27 expression,
and those that have a very low percentage (4 %) are IgD−CD27−
(DN). Moreover, CD19+CD38−CD24− B cells, principally IgD−,
are IgD−CD27+/IgD−CD27−
AGE
as no differences have been observed among the groups
of age studied, the figure shows representative histograms
of IgM, CD5, and CD180 expression. As shown, the
largest proportion of CD19+CD38hiCD24hi cells (≥80 %
IgD+CD27 − ) wa s I gM+CD5+ , whe r e a s o f
CD19+CD38intCD24int cells (≥80 % IgD+CD27−),
IgM±CD5±, and of CD19+CD38−CD24+ cells
(IgD±CD27±), IgM+CD5−, as previously demonstrated
(Carsetti et al. 2004; Palanichamy et al. 2009; Blair et
al. 2010). Finally, the CD19+CD38−CD24− population
(IgD−CD27±) not thus far described was found to be
IgM−CD5+. Moreover, the analysis of CD180 expression
revealed that almost all CD180-negative B cells are gated
within the CD19+CD38−CD24− population, whereas
classical transitional, mature naïve, and primarily memo-
ry cells were positive for this marker. Results depicted in
Fig. 2 are representative of all subjects (young, old,
centenarian offspring, and age matched) analyzed.
CpG+PMA/ionomycin stimulates intracellular
cytokine production by human blood B cells in vitro
A typical feature of aging is a chronic, low-grade inflam-
mation characterized by a general increase in the produc-
tion of pro-inflammatory cytokines and inflammatory
markers (Cevenini et al. 2010). Memory and naïve B
cells can produce different cytokines and chemokines;
in particular, memory B cells produce high levels of the
pro-inflammatory cytokines IL-1α, IL-1β, IL-6, and
TNF-α, suggesting that B cells might take part in the
generation or in the maintenance of the inflammatory
environment of the elderly (Agrawal and Gupta 2011).
To study the functional properties of peripheral blood B
lymphocytes, we tested their ability to produce cytokines
“in vitro” on stimulation with a combination of CpG,
PMA, and ionomycin. We evaluated the production of
IL-10, an anti-inflammatory cytokine, and IL-6 and TNF-
α, two pro-inflammatory cytokines, by CD38/CD24 B
cell subsets. These cytokines have been extensively stud-
ied in aging, as they are involved in the control (IL-10) or
maintenance (IL-6 and TNF-α) of inflammation, one of
main characteristics of aged people (inflamm-aging)
(Franceschi et al. 2000a; Lio et al. 2003; Sanjabi et al.
2009). Our analysis revealed that in all the subjects
studied, 5 h after stimulation, the main IL-10-producing
cells were of the CD19+CD38hiCD24hi phenotype
(Table 1). In contrast, CD19+CD38−CD24+ and
CD19+CD38−CD24− cells are the more responsive B cell
populations involved in TNF-α production (Table 2). As
no differences were detected (not shown) regarding the
age classes, the tables show the mean fluorescent inten-
sity (MFI) values (mean±SEM) of all the subjects stud-
ied. On the other hand, this kind of stimulation was not
able to induce IL-6 production. Indeed, we did not detect
Fig. 2 Evaluation of IgM, CD5, and CD180 on CD38/CD24 B
cells. A typical experiment showing the expression of the immu-
nological markers on CD19+CD38hiCD24hi, CD19+CD38intC-
D24int, CD19+CD38−CD24+, and CD19+CD38−CD24− B cell
subsets. Histograms are a representative of all subjects (young,
old, CO, and age matched) analyzed. As shown, CD5 is well
expressed on CD19+CD38hiCD24hi and CD19+CD38−CD24−
(MFI 789 and 704, respectively); a lower level is expressed on
CD19+CD38intCD24int (MFI 570), whereas CD19+CD38−CD24+
cells show the lowest level of expression of CD5 (MFI 278).
Concerning IgM, CD19+CD38hiCD24hi and CD19+CD38−CD24+
cells are IgM+ (MFI 1,601 and 1,489, respectively);
CD19+CD38intCD24int cells are IgM± (MFI 682), whereas
CD19+CD38−CD24− cells show the lowest level of expression
of IgM (MFI 391). The evaluation of CD180 on CD38/CD24 B
cell subsets has revealed that CD19+CD38hiCD24hi (MFI 1,578),
CD19+CD38intCD24int (MFI 1,413), and CD19+CD38−CD24+
(MFI 1,507) cells are CD180+, whereas CD19+CD38−CD24− cells
show the lowest level of expression of CD180 (MFI 484), result-
ing to CD180−
AGE
T
ab
le
1
IL
-1
0
pr
od
uc
tio
n
by
C
D
38
/C
D
24
B
ce
ll
su
bs
et
s
w
ith
or
w
ith
ou
t
C
pG
/P
M
A
/io
no
m
yc
in
st
im
ul
at
io
n
IL
-1
0
R
P
M
I
C
pG
/P
M
A
/io
no
m
yc
in
C
D
38
/C
D
24
B
ce
ll
su
bs
et
s
M
F
I
va
lu
es
(m
ea
n
±
S
E
M
)
C
D
38
h
i C
D
24
h
i
(1
,1
2
6
.4
±
2
0
8
.3
)
C
D
38
in
t C
D
24
in
t
(6
11
.7
±
1
2
7
.6
)
C
D
38
− C
D
24
+
(4
8
1
.4
±
4
5
.1
)
C
D
38
− C
D
24
−
(3
4
1
.6
±
5
7
.7
)
C
D
38
/C
D
24
B
ce
ll
su
bs
et
s
M
F
I
va
lu
es
(m
ea
n
±
S
E
M
)
C
D
38
h
i C
D
24
h
i
(2
,1
5
0
.2
±
3
1
6
.7
)
C
D
38
in
t C
D
24
in
t
(1
,0
3
9
.4
±
2
7
6
)
C
D
38
− C
D
24
+
(7
8
4
±
7
5
.9
)
C
D
38
− C
D
24
−
(5
7
6
±
1
2
3
.7
)
C
D
38
h
i C
D
24
h
i
(1
,1
2
6
.4
±
2
0
8
.3
)
–
p1
0
0.
03
p2
0
0.
02
p3
0
0.
00
5
C
D
38
h
i C
D
24
h
i
(2
,1
5
0
.2
±
3
1
6
.7
)
–
p1
0
0.
00
2
p2
0
0.
00
1
p3
0
0.
00
01
C
D
38
in
t C
D
24
in
t
(6
11
.7
±
1
2
7
.6
)
p1
0
0.
03
–
p4
0
0.
6
p5
0
0.
03
C
D
38
in
t C
D
24
in
t
(1
,0
3
9
.4
±
2
7
6
)
p1
0
0.
00
2
–
p4
0
0.
1
p5
0
0.
04
C
D
38
− C
D
24
+
(4
8
1
.4
±
4
5
.1
)
p2
0
0.
02
p4
0
0.
6
–
p6
0
0.
01
C
D
38
− C
D
24
+
(7
8
4
±
7
5
.9
)
p2
0
0.
00
1
p4
0
0.
1
–
p6
0
0.
02
C
D
38
− C
D
24
−
(3
4
1
.6
±
5
7
.7
)
p3
0
0.
00
5
p5
0
0.
03
p6
0
0.
01
–
C
D
38
− C
D
24
−
(5
7
6
±
1
2
3
.7
)
p3
0
0.
00
01
p5
0
0.
04
p6
0
0.
02
–
S
ta
tis
tic
al
ly
si
gn
if
ic
an
t
di
ff
er
en
ce
s
ar
e
m
ar
ke
d
in
bo
ld
A
to
ta
l
of
35
he
al
th
y
S
ic
ili
an
s
w
er
e
an
al
yz
ed
.C
D
19
+
C
D
38
h
i
C
D
24
h
i
is
th
e
m
ai
n
B
ce
ll
su
bs
et
in
vo
lv
ed
in
IL
-1
0
pr
od
uc
tio
n.
D
at
a
ar
e
ex
pr
es
se
d
as
M
F
I
va
lu
es
(m
ea
n
±
S
E
M
).
p1
0
C
D
19
+
C
D
38
h
i
C
D
24
h
i
vs
C
D
19
+
C
D
38
in
t
C
D
24
in
t
;
p2
0
C
D
19
+
C
D
38
h
i
C
D
24
h
i
vs
C
D
19
+
C
D
38
−
C
D
24
+
;
p3
0
C
D
19
+
C
D
38
h
i
C
D
24
h
i
vs
C
D
19
+
C
D
38
−
C
D
24
−
;
p4
0
C
D
19
+
C
D
38
in
t
C
D
24
in
t
vs
C
D
19
+
C
D
38
−
C
D
24
+
;
p5
0
C
D
19
+
C
D
38
in
t
C
D
24
in
t
vs
C
D
19
+
C
D
38
−
C
D
24
−
;
p6
0
C
D
19
+
C
D
38
−
C
D
24
+
vs
C
D
19
+
C
D
38
−
C
D
24
−
AGE
T
ab
le
2
T
N
F
-α
pr
od
uc
tio
n
by
C
D
38
/C
D
24
B
ce
ll
su
bs
et
s
w
ith
or
w
ith
ou
t
C
pG
/P
M
A
/io
no
m
yc
in
st
im
ul
at
io
n
T
N
F
-α
R
P
M
I
C
pG
/P
M
A
/io
no
m
yc
in
C
D
38
/C
D
24
B
ce
ll
su
bs
et
s
M
F
I
va
lu
es
(m
ea
n
±
S
E
M
)
C
D
38
h
i C
D
24
h
i
(2
0
2
.1
±
1
9
.2
)
C
D
38
in
t C
D
24
in
t
(9
4
±
1
4
.2
)
C
D
38
− C
D
24
+
(9
7
.3
±
1
5
.8
)
C
D
38
− C
D
24
−
(7
6
.7
±
1
2
)
C
D
38
/C
D
24
B
ce
ll
su
bs
et
s
M
F
I
va
lu
es
(m
ea
n
±
S
E
M
)
C
D
38
h
i C
D
24
h
i
(2
9
7
.4
±
2
6
.2
)
C
D
38
in
t C
D
24
in
t
(3
4
1
.9
±
5
1
.1
)
C
D
38
− C
D
24
+
(5
7
4
.5
±
8
0
.1
)
C
D
38
− C
D
24
−
(6
5
3
±
1
5
2
.7
)
C
D
38
h
i C
D
24
h
i
(2
0
2
.1
±
1
9
.2
)
–
p1
0
0.
00
3
p2
0
0.
00
04
p3
0
0.
00
01
C
D
38
h
i C
D
24
h
i
(2
9
7
.4
±
2
6
.2
)
–
p1
0
0.
8
p2
0
0.
05
p3
0
0.
00
6
C
D
38
in
t C
D
24
in
t
(9
4
±
1
4
.2
)
p1
0
0.
00
3
–
p4
0
0.
7
p5
0
0.
3
C
D
38
in
t C
D
24
in
t
(3
4
1
.9
±
5
1
.1
)
p1
0
0.
8
–
p4
0
0.
04
p5
0
0.
1
C
D
38
− C
D
24
+
(9
7
.3
±
1
5
.8
)
p2
0
0.
00
04
p4
0
0.
7
–
p6
0
0.
4
C
D
38
− C
D
24
+
(5
7
4
.5
±
8
0
.1
)
p2
0
0.
05
p4
0
0.
04
–
p6
0
0.
7
C
D
38
− C
D
24
−
(7
6
.7
±
1
2
)
p3
0
0.
00
01
p5
0
0.
3
p6
0
0.
4
–
C
D
38
− C
D
24
−
(6
5
3
±
1
5
2
.7
)
p3
0
0.
00
6
p5
0
0.
1
p6
0
0.
7
–
S
ta
tis
tic
al
ly
si
gn
if
ic
an
t
di
ff
er
en
ce
s
ar
e
m
ar
ke
d
in
bo
ld
A
to
ta
lo
f
35
he
al
th
y
S
ic
ili
an
s
w
er
e
an
al
yz
ed
.T
he
m
aj
or
co
nt
ri
bu
tio
n
to
th
e
pr
od
uc
tio
n
of
T
N
F
is
se
en
fr
om
C
D
38
−
C
D
24
+
an
d
C
D
38
−
C
D
24
−
ce
lls
.D
at
a
ar
e
ex
pr
es
se
d
as
M
F
I
va
lu
es
(m
ea
n
±
S
E
M
).
p1
0
C
D
19
+
C
D
38
h
i
C
D
24
h
i
vs
C
D
19
+
C
D
38
in
t
C
D
24
in
t
;p
2
0
C
D
19
+
C
D
38
h
i
C
D
24
h
i
vs
C
D
19
+
C
D
38
−
C
D
24
+
;p
3
0
C
D
19
+
C
D
38
h
i
C
D
24
h
i
vs
C
D
19
+
C
D
38
−
C
D
24
−
;
p4
0
C
D
19
+
C
D
38
in
t
C
D
24
in
t
vs
C
D
19
+
C
D
38
−
C
D
24
+
;
p5
0
C
D
19
+
C
D
38
in
t
C
D
24
in
t
vs
C
D
19
+
C
D
38
−
C
D
24
−
;
p6
0
C
D
19
+
C
D
38
−
C
D
24
+
vs
C
D
19
+
C
D
38
−
C
D
24
−
AGE
a significant increase in production of IL-6 compared to
unstimulated PBMC (not shown).
Age-related changes result in altered distribution
of naïve/memory subsets
We have determined whether the distribution of B cell
phenotypes including the newly defined subset is different
in the elderly compared to the young, and whether this is
different in centenarian offspring compared to age-
matched and elderly controls (Table 3).We did not observe
any significant differences in the CD19+CD38hiCD24hi
(Fig. 3a) or CD19+CD38intCD24int (Fig. 3b) populations
between any groups of subjects tested. However, we ob-
served a trend towards higher proportions of
CD19+CD38−CD24+ cells in the elderly. Interestingly,
the percentage of these cells in centenarian offspring are
more similar to what is observed in young donors than the
age-matched (AM) controls (Fig. 3c). Most strikingly, the
CD19+CD38−CD24− population was highly significantly
enriched in the older subjects. Again, their distribution in
CO fell between the young and the elderly in the general
population (Fig. 3d).
CD180-negative B cells and CD180 expression
on CD38/CD24 and IgD/CD27 B cell subsets
in different age groups
It is known that immune system of elderly people shows
some characteristics typical of chronically stimulated
subjects (CMV-positive elderly subjects and HIV and
SLE patients). Moreover, circulating B cells have been
reported to lack the TLR-4 homologue CD180 (RP105)
in chronically stimulated SLE patients (Koarada and
Tada 2012). We therefore analyzed the percentage of
CD19+CD180− B lymphocytes in PBMC of young, el-
derly, CO, and their AM controls. Figure 4a shows a
significant increase of this population in the elderly rela-
tive to the young. However, no differences were seen
between CO and AM controls, although the percentage
of CD180− B cells in CO and AM controls are higher
than in the young but lower than in the old donors. Next,
we have evaluated the level of expression of CD180 in
the four subsets identified on the basis of the markers
CD38 and CD24 in the four age groups (Fig. 4b). The
phenotypic characterization of CD38/CD24 B cells has
shown that most CD19+CD38−CD24−B cells are CD180
negative (data shown in Fig. 2). Our comparative analysis
between young, CO, AM, and old (O) subjects did not
reveal age-associated changes in the level of CD180
expression. Moreover, as we have observed that
CD19+CD38−CD24− B cells mainly include both
switched memory (IgD−CD27+) and DN (IgD−CD27−)
B cells, we have also evaluated the expression of CD180
on B cell subsets identified on the basis of the expression
of IgD and CD27 (Fig. 4c). Interestingly, in all the sub-
jects, this analysis revealed a progressive decrease of
CD180 expression through the different stages of matu-
ration, from naïve (IgD+CD27−) to memory-switched
(IgD−CD27+) and DN (IgD−CD27−) B cells and from
CD19+CD38hiCD24hi to CD19+CD38−CD24− B cells,
although the comparative study did not show any
changes between age classes.
Age-related differences in the distribution of IgM+CD27−
(naïve mature), IgD+IgM+CD27+ (natural effector),
and IgD−IgM+CD27+ (IgM only) B cell phenotypes
The complexity of the memory B cell pool is further
documented by the evidence of different IgM+ B cell
Table 3 Distribution of CD38/CD24 B cell phenotypes in young, centenarian offspring, age-matched controls, and old subjects
CD38/CD24 B cell subsets Age groups P value
Y CO AM O p1 p2 p3 p4 p5 p6
CD19+CD38highCD24high 4.1±1.3 2.8±0.7 3.9±1.3 3.8±1.5 0.9 0.5 0.9 0.7 0.8 0.7
CD19+CD38intCD24int 66.8±3.1 54.3±11.5 54.8±4.3 54.5±9.6 0.4 1 0.1 1 1 1
CD19+CD38−CD24+ 4.1±0.8 4.2±0.9 5.7±1.1 6.6±0.6 0.06 0.2 0.4 1 0.2 0.7
CD19+CD38−CD24− 0.9±0.3 3.1±1.4 15.4±3.1 9.4±4.7 0.03 0.02 0.01 0.06 0.3 0.5
Statistically significant differences are marked in bold
Percentage values are expressed as mean±SEM. Differences between age groups were analyzed with the Mann–Whitney test. p10Yvs
O; p20CO vs AM; p30Y vs AM; p40Y vs CO; p50CO vs O; p60AM vs O
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phenotypes presumably representing different stages of
B cell differentiation. We and others have demonstrated
that IgM B lymphocytes are reduced in the elderly (Shi
et al. 2005; Buffa et al. 2011). As the previous pheno-
typic characterization has not revealed differences in the
IgM expression, we chose to analyze IgM+ B cell phe-
notypes on our samples according to the Berkowska
gating strategy (Berkowska et al. 2011), based on the
major subset of CD38dimCD24dim, excluding transition-
al B cells (Fig. 5). So, CD38dimCD24dim B cells can be
separated into three IgM populations: IgM+CD27−
(naïve mature), IgD+IgM+CD27+ (natural effector),
and IgD−IgM+CD27+ (IgM only) (Fig. 5a). A compar-
ison between our subjects confirmed (Shi et al. 2005;
Buffa et al. 2011) a different distribution of B cells
identified on the basis of these markers between young
and old donors and revealed that CO possess a more
“youthfully” distributed immune profile compared with
age-matched controls. Indeed, the percentage of
IgM+CD27− (naïve mature) cells (Fig. 5b) are signifi-
cantly greater in CO, a group of people presumably
advantaged for longevity. The analysis of the other
two IgM+CD27+ memory B cell phenotypes revealed
significantly fewer of these memory cells in the CO
(Fig. 5c, d).
Discussion
During aging, the immune system progressively loses its
ability to fight off infections and to respond as quickly or
as efficiently to different stimuli. Moreover, the inability
of old individuals to effectively respond to vaccines
results in less effective immunizations against viruses
and bacteria, thus increasing the risk of infections and
diseases (Miller and Cancro 2007; Cancro et al. 2009;
Gibson et al. 2009; Dunn-Walters and Ademokun 2010;
Frasca and Blomberg 2011). Indeed, it is well docu-
mented that the immune response to vaccination
declines with age, although the reasons for this are
poorly understood (Kumar and Burns 2008; Frasca et
al. 2010; McElhaney et al. 2012). It is also known that in
the elderly, there is an impairment of both innate and
adaptive immune responses. As we age, the numbers of
critical cells in the immune system change, and many
may become less functional. However, innate immunity
seems to be better preserved, while more severe age-
dependent changes occur in the adaptive immune sys-
tem (Franceschi et al. 2000b). There are clear changes in
B cell generation and repertoire, and as a consequence
of this and changes in the T cells, elderly people show
defective humoral immunity (Cancro et al. 2009; Bulati
Fig. 3 Distribution of B cell
phenotypes in young, old,
centenarian offspring, and
age-matched controls. Per-
centage of
CD19+CD38hiCD24hi (a)
and CD19+CD38intCD24int
(b) B cell populations do not
change when analyzed in
different age groups. c Trend
towards an increase in the
age-related
CD19+CD38−CD24+ B cell
subset. d Significant in-
crease of the
CD19+CD38−CD24− B cell
subset in elderly people (old
and AM) when compared to
young. CO, like young,
show a lower percentage of
this population when com-
pared to their age-matched
controls. Differences be-
tween age groups were ana-
lyzed with the Mann–
Whitney test. *P<0.05
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et al. 2011; Frasca and Blomberg 2011). There is a
decrease both in percentage and absolute number of
total B lymphocytes (Pawelec et al. 2005; Shi et al.
2005; Frasca et al. 2008; Veneri et al. 2009; Bulati et
al. 2011), and in previous papers, we (Colonna-Romano
et al. 2009) and others (Gupta et al. 2005) have demon-
strated that the percentage of naïve B cells are signifi-
cantly reduced in aged individuals. However, this is still
a somewhat controversial finding as some authors
reported an increase, a decrease, or no changes in the
naïve/memory B cell compartments, as we have reviewed
(Bulati et al. 2011). The CD27+ memory B cells and, in
particular, the IgM memory CD19+IgM+IgD+CD27+
cells, which are considered to be the recirculating equiv-
alent of murine marginal zone cells, have been shown to
decline in both proportion and numbers with age (Shi et
al. 2005; Buffa et al. 2011). In a previous study, we
documented the expansion of CD19+IgD−CD27− cells,
a DNmemory B cell population, in the elderly (Colonna-
Romano et al. 2009). This population is also expanded in
subjects chronically stimulated (Anolik et al. 2004;Wei et
al. 2007; Sanz et al. 2008; Cagigi et al. 2009) and might
be considered the result of long-enduring stimulation.
However, not all subjects or population groups are equal-
ly susceptible to the effects of long-term chronic stimu-
lation of the immune system. Indeed, recent evidence has
shown a well-preserved immune profile of a group of
healthy elderly centenarian offspring who seem to have
genetic and functional advantages associated with the
reduced risk of disability with age (Terry et al. 2003,
2004). We have demonstrated that the naïve B cells
subset is well preserved in CO compared with the age-
Fig. 4 CD180-negative B cells and CD180 expression on
CD38/CD24 and IgD/CD27 B cell subsets. a Evaluation of
CD19+CD180 (RP105)− B cell population among the different
age groups analyzed. Old people show a significant increase in
the percentage of the B cell subset lacking CD180 expression,
when compared with young. b Histograms show CD180-
negative B cells among CD38hiCD24hi, CD38intCD24int,
CD38−CD24+, and CD38−CD24− B cell compartments in young
(Y), centenarian offspring (CO), age-matched (AM), and old (O)
subjects. A progressive increase in percentage of CD180-
negative cells from CD38hiCD24hi to CD38−CD24− cells has
been demonstrated without age-related changes between groups
studied. c Expression of CD180 on naïve memory B cells
identified on the basis of the expression of IgD and CD27. A
progressive down-modulation of CD180 from naïve
(IgD+CD27−) to DN (IgD−CD27−) B cells has shown but, again,
no change between age classes. Differences between age groups
were analyzed with the Mann–Whitney test. *P<0.05. Bar
graphs indicate mean±SEM
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matched controls. The mirror image of this is a more
restricted memory pool, which includes, in addition, a
less expanded DN compartment (Colonna-Romano et al.
2010). Collectively, our data suggest age-related changes,
but they are of course cross-sectional in the present study
and therefore can only formally demonstrate differences
between groups. Other investigations, such as a longitu-
dinal follow-up studies, will be necessary to affirm a real
age-related change.
Recently, several new B cell populations have been
described, although their phenotype has not been always
associated with established biological function. In the
present work, we gained insight into the naïve/memory
B cell compartment focusing, in particular, on the different
age groups analyzed. According to the gating strategy
proposed by Carsetti et al. (2004), our study has focused
on four distinct B cell populations: CD19+CD38hiCD24hi
(classical transitional), CD19+CD38intCD24int (mature
naïve), CD19+CD38−CD24+ (primarily memory), and in
addition, a not previously described CD19+CD38−CD24−
population. A previous study reported that the frequency
of transitional B cells is rapidly reduced during the first
years of life, stabilizing after 5 years of age (Morbach et al.
2010). Here, we found that there are no differences in the
percentage of transitional and mature naïve B cells, com-
paring young and the three different groups of old donors
CO, AM, and elderly, but we did observe a higher pro-
portion of CD19+CD38−CD24+ primarily memory cells
in young and CO compared to AM, although the differ-
ence did not achieve statistical significance. However, the
Fig. 5 Diversity in the human IgM+ B cell compartment and
distribution in young and old, centenarian offspring (CO), and their
age-matched (AM) controls. a Within the CD19+ B cell compart-
ment, B lymphocytes are characterized on the basis of CD38 and
CD24 expression. According to the Berkowska et al. (2011) gating
strategy, CD38dimCD24dim B lymphocytes were subdivided on the
basis of IgM and CD27 expressions, defining IgM+CD27− naïve
mature. Subsequently, on the basis of IgD expression, IgM+CD27+
B cells were gated into IgD+IgM+CD27+ natural effector and
IgD−IgM+CD27+ IgM only. b Young donors have a significant
higher percentage of naïve mature cells compared to the elderly. A
direct comparison between CO and aged people (AM and old
subjects) emphasizes that the former shows a significantly higher
percentage of this IgM population. c A substantial and significant
age-related decrease was observed in the natural effector subset. d
Age-related decrease of the IgM-only B cell subset observed in old
and age-matched controls compared with young and centenarian
offspring subjects. Differences between age groups were analyzed
with the Mann–Whitney test. *P<0.05; **P<0.01; ***P<0.001
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CD19+CD38−CD24− putative new population was signif-
icantly increased in the elderly, and the percentage of this
population in CO is more similar to that observed in
young than in elderly or age-matched donors. This may
therefore contribute to their immunological “youthful-
ness.” Apart from this, the other B cell populations iden-
tified on the basis of the expression of CD38/CD24 show
the same distribution in the different groups studied. The
evaluation of both IgD and CD27 on CD38/CD24 B cells
also supports the developmental dynamic from tran-
sitional B cells that are mainly IgD+CD27− (naïve),
through mature naïve B cells, in which we observe
the progressive appearance of CD27, which is, final-
ly, most strongly expressed on the primarily memory
CD19+CD38−CD24+, together with the progressive
loss of IgD. CD19+CD38−CD24+ B lymphocytes,
also known as primarily memory B cells, show a
variety of different phenotypes. Although more than
70 % are CD27+, the simultaneous evaluation of IgD
and CD27 has revealed that some of them (27 %) are
IgD+CD27+ (unswitched memory); others (44 %) are
IgD−CD27+ (switched memory); 25 % of them are
naïve, as they express IgD, and are negative for
CD27 expression, and those that have a very low
percentage (4.3 %) are IgD−CD27− (DN). Some
authors have shown that this population should in-
clude only memory B cells, although their analyses
have revealed a percentage of CD27-negative B cells
gated inside the aforementioned subset (Carsetti et al.
2004; Blair et al. 2010). Unfortunately, those authors did
not report the percentage of CD27−, so we cannot nu-
merically compare our data with the data reported in their
papers. Further analyses are necessary to elucidate this
point. Focusing on CD19+CD38−CD24− B lympho-
cytes, we did not observe any changes in distribution
of IgD/CD27 phenotypes in the different age groups.
Moreover, here, we show that about half of these cells
are IgD−CD27+-switched memory, not different in the
elderly (Colonna-Romano et al. 2009; Buffa et al. 2011),
whereas almost 30 % of them are IgD−CD27− DN B
cells that are increased in the elderly but not in CO
(Colonna-Romano et al. 2009, 2010). It is of note that
a fraction of the IgD−CD27+ subset also includes
IgD−IgM+CD27+ memory B cells that we and others
have described as being decreased in the elderly (Shi et
al. 2005; Buffa et al. 2011). Probably, their low percent-
age does no t in f luence the pe rcen tage of
CD19+CD38−CD24− B cells in the different age groups.
The evaluation of IgM has revealed that this marker is
strongly expressed on CD19+CD38hiCD24hi and on
IgD+CD27− cells (Colonna-Romano et al. 2009) and
tends to disappear from both CD19+CD38−CD24− and
IgD−CD27− cells. We have also evaluated CD5 expres-
sion on CD38/CD24 B cell phenotypes. Our analysis
revealed that all different subpopulations had different
levels of CD5. Our characterization of CD38/CD24 B
cells has confirmed that CD19+CD38hiCD24hi cells were
positive for CD5. Interestingly, CD19+CD38−CD24−
cells were also positive for the same marker. This mol-
ecule is present in adulthood on all B cell subsets, but at a
low and variable frequency. CD5 expression is associat-
ed with the presence of the B cell receptor (BCR), and it
appears in the bone marrow; it has been shown to be a
negative regulator of BCR signaling, and its expression
may be a marker of antigen exposure (Gary-Gouy et al.
2000, 2002; Carsetti et al. 2004). Additional character-
ization of these CD19+CD38−CD24−B lymphocytes has
demonstrated here that almost all are CD180 negative.
This marker, also known as RP105, is a toll-like
receptor-associated molecule, originally identified as a
B cell surface molecule mediating activation and prolif-
eration in mice. Data from the literature indicate that
RP105-deficient mice are hypo-responsive to TLR-4
and TLR-2 stimulation (Ogata et al. 2000; Nagai et al.
2005). Recently, increasing interest in this molecule has
led several investigators to evaluate CD180 in humans
and, in particular, in subjects suffering from autoimmune
diseases. It has been demonstrated that the percentage of
CD180-negative B cells are significantly increased in
systemic lupus erythematosus and, to a lesser extent, in
rheumatoid arthritis patients, compared to healthy con-
trols. Its expression declines during the inactive stages of
disease, suggesting that the expansion of this population
is correlated with disease activity (Koarada and Tada
2012). The phenotypic characterization of the above-
described subset has defined a profile of activated B cells
producing immunoglobulins and anti-dsDNA antibod-
ies. Moreover, approximately 50 % of these CD180-
negative B cells had intracellular IgG (Koarada et al.
1999), suggesting that they could be induced to differ-
entiate into IgG-secreting B cells by certain stimuli. As
autoimmune phenomena are a common feature in the
elderly, we have evaluated the expression of this marker
on total B lymphocytes in different age groups, observ-
ing a reduced expression with age. Indeed, CD180-
negative B cells are significantly increased in the very
elderly donors (age range 86.4±3.8) when compared to
the young (age range 28.5±1.9), but not in CO and AM
AGE
(age range 70.1±8.3 and 69.1±9, respectively).
Furthermore, we assessed the level of expression of
CD180 in the four subsets identified on the basis of
the markers CD38 and CD24 in the four age groups.
In any event, our comparative analysis between young,
CO, AM, and O subjects did not reveal age-associated
differences in the level of CD180 expression.
Interestingly, the evaluation of CD38−CD24−CD180−
B cells gated inside CD19+ B cell population has shown
a trend (not significant) towards higher proportions in
elderly donors and age-matched controls when com-
pared with young donors and centenarian offspring (da-
ta not shown). Moreover, as we have observed that
CD19+CD38−CD24− B cells, which are increased in
elderly people when compared to young donors and in
age-matched controls more than in centenarian off-
spring, mainly include both switched memory
(IgD−CD27+) and DN (IgD−CD27−) B cells, we have
also evaluated the expression of CD180 on IgD/CD27 B
cell subpopulations. As expected, we saw a lower ex-
pression of this marker from naïve to memory-switched
and DN B cells, although the comparative analysis did
not show any changes between age classes. Data
obtained from CD180 evaluation on CD38/CD24 and
IgD/CD27 phenotypes cannot be considered similar,
although, in both gating systems, CD180-negative B
cells are increased from naïve to memory B cells.
Thus, reduced expression of the TLR-associated mole-
cule CD180 on total B cells is observed in the elderly,
and an age- re la ted increase of DN and of
CD19+CD38−CD24− B cells, at least defective for
CD180, could be related to the increased susceptibility
to Gram-negative bacterial diseases of elderly people.
Indeed, it is known that elderly people are more suscep-
tible than the young to pneumococcal infection. The
decline of the IgM memory B cell pool in the elderly
could also be involved in defective immune responses
against infections by encapsulated bacteria.
On the basis of IgM, CD27, and IgD expression, IgM
B lymphocytes can be subdivided into IgM+CD27−
“naïve mature,” IgD−IgM+CD27+ IgM-only, and
IgD+IgM+CD27+ “natural effector” B cells. As the pre-
vious phenotypic characterization of CD38/CD24 B
cells has not revealed differences in the IgM expression,
we chose to analyze IgM+ B cell phenotypes on our
samples according to the Berkowska gating strategy
(Berkowska et al. 2011), based on the major subset of
CD38dimCD24dim. We analyzed IgM B cell subsets,
comparing data between subjects included in this study.
We have confirmed data from the literature demonstrat-
ing impairment decrease of IgM B lymphocytes in the
elderly (Shi et al. 2005; Buffa et al. 2011). On the
contrary, a further evaluation of CO B cell populations
revealed that the percentage of these cells are not re-
duced to the same extent as their age-matched controls
and remain more similar to that observed in young
people. These data reinforce our previous hypothesis
according to which CO have a younger B cell profile.
This hypothesis is corroborated by the reduced number
of CD19+CD38−CD24− B cells and a higher level of
IgMB cell subsets in CO, compared to AM donors. This
immunological advantage, likely due to a good bone
marrow reservoir, could help CO both to fight the main
age-related diseases and to maintain healthy aging.
Here, we have also performed a preliminary func-
tional study on the CD38/CD24 B cells to better under-
stand their biological role and function. We tested their
ability to produce pro- and anti-inflammatory cytokines
on strong stimulation with CpG/PMA/ionomycin in
vitro. We know that cytokines are considered key play-
ers in maintaining lymphocyte homeostasis. Their func-
tion is to induce and modulate the nature of the response
after an immune insult, or in contrast, they may cause
non-responsiveness and active immune suppression
(Sanjabi et al. 2009). Moreover, it is known that elderly
people show a pro-inflammatory microenvironment that
has been related to the increased risk of morbidity and
mortality (Licastro et al. 2005; Vasto et al. 2007).
Concerning the anti-inflammatory cytokine IL-10, also
our stimulation system provides data consistent with a
biological role of CD19+CD38hiCD24hi cells as regula-
tory cells, i.e., a B cell population involved in IL-10
production. Our comparative analysis did not reveal any
differences between the four age groups analyzed. We
have previously demonstrated that under the same con-
ditions, IgD+CD27− (naïve) B cells produce high levels
of IL-10 in the elderly (Buffa et al. 2011). Although we
have confirmed that CD19+CD38hiCD24hi cells are
mainly IgD+CD27−, our analysis of CD38/CD24 pop-
ulations revealed a certain percentage of naive IgD/
CD27 in all four populations analyzed, extending the
potential role of IL-10-producing cells. Finally, regard-
ing the pro-inflammatory cytokine TNF-α, the
CD19+CD38−CD24+ and CD19+CD38−CD24− B cell
subsets, which seem to be sensitive to biological and not
chronological aging, are the main B cells involved in the
in vitro production of this pro-inflammatory cytokine,
with no differences between the groups studied. At the
AGE
present time, we cannot state which population is more
responsible for the impaired cytokine production.
Nonetheless, as TNF-α is a pro-inflammatory cytokine
recently reported to be increased in a mouse model made
of aged B cells (Frasca et al. 2012), we hypothesize that
swi tched memory (IgD−CD27+) and/or DN
(IgD−CD27−) B cells could be responsible for this cyto-
kine production. We suggest that the expansion of these
B cell subsets in the elderly might contribute to the
increased inflammatory status designated “inflamm-
aging.”
Taken together, our data document the phenotypic
and biological characteristics of a CD19+CD38−CD24−
B cell population and suggest that these cells might act
as memory B cells involved in inflammation. Analysis
with additional markers, such as IgG, IgA, HLA,
CD138, CD43, and CD70, may be useful for a deeper
characterization of this subset, as well as investigating
them under pathological conditions. We also need to
evaluate if they might act as antibody (Ab)-producing
cells or develop into Ab-secreting cells, and in particu-
lar, whether these cells could be responsible for autoan-
tibody production. Moreover, our data emphasize that
modifications to B cell immunity could play a pivotal
role during processes associated with aging. A better
understanding of B cell immunosenescence is crucial for
the improvement of the quality of life of the growing
elderly population worldwide. Hence, B cell immune
profiling must be included in any attempts to develop
useful biomarkers of human immunosenescence. The
study of B cell phenotypes in the peripheral blood of
centenarian offspring revealed that many parameters are
well preserved and more closely resemble that of the
young than of either their age-matched controls or old
subjects. In any event, other immune parameters, such
as CD180 expression and cytokine production, seem not
suggest a complete preservation of the B cell branch in
the offspring of long-lived subjects. Further analyses are
necessary to correlate the environmental and genetic
background with a well-preserved immune system of
centenarian offspring that could support the hypothesis
of a “familial youth” of the immune system.
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